Biochim Biophys Acta 1771(8): 952-960

Modulation of PPAR activity via phosphorylation

Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, Penn State University, University Park, PA 16802

^{To whom correspondence should be addressed: Jack Vanden Heuvel, PhD, Professor of Molecular Toxicology, Penn State University, 325 Life Sciences Building, University Park, PA 16802, T: (814) 863-8532, F: (814) 863-1696,}ude.usp@2vpj, jackvh.cas.psu.edu

Publisher's Disclaimer

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily of transcription factors that respond to specific ligands by altering gene expression in a cell-, developmental- and sex-specific manner. Three subtypes of this receptor have been discovered (PPARα, β and γ), each apparently evolving to fulfill different biological niches. PPARs control a variety of target genes involved in lipid homeostasis, diabetes and cancer. Similar to other nuclear receptors, the PPARs are phosphoproteins and their transcriptional activity is affected by cross-talk with kinases and phosphatases. Phosphorylation by the mitogen-activated protein kinases (ERK- and p38-MAPK), Protein Kinase A and C (PKA, PKC), AMP Kinase (AMPK) and glycogen synthase kinase-3 (GSK3) affect their activity in a ligand-dependent or -independent manner. The effects of phosphorylation depend on the cellular context, receptor subtype and residue metabolized which can be manifested at several steps in the PPAR activation sequence including ligand affinity, DNA binding, coactivator recruitment and proteasomal degradation. The review will summarize the known PPAR kinases that directly act on these receptors, the sites affected and the result of this modification on receptor activity.

Abstract

Footnotes

^{G.H. Perdew, Penn State University, unpublished results.}

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Footnotes

References

1. N.R.N. Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97:161–163.[PubMed]
2. Escher P, Wahli WPeroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res. 2000;448:121–138.[PubMed][Google Scholar]
3. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli WDifferential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, - beta, and -gamma in the adult rat. Endocrinology. 1996;137:354–366.[PubMed][Google Scholar]
4. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx JThe organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997;272:18779–18789.[PubMed][Google Scholar]
5. Issemann I, Green SActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650.[PubMed][Google Scholar]
6. Gottlicher M, Widmark E, Li Q, Gustafsson JAFatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1992;89:4653–4657.[Google Scholar]
7. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli WControl of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879–887.[PubMed][Google Scholar]
8. Sher T, Yi HF, McBride OW, Gonzalez FJcDna cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598–5604.[PubMed][Google Scholar]
9. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MDThiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996;137:4189–4195.[PubMed][Google Scholar]
10. Dowell P, Peterson VJ, Zabriskie TM, Leid MLigand-induced peroxisome proliferator-activated receptor alpha conformational change. J Biol Chem. 1997;272:2013–2020.[PubMed][Google Scholar]
11. Tien ES, Hannon DB, Thompson JT, Vanden Heuvel JPExamination of ligand-dependent coactivator recruitment by Peroxisome Proliferator-Activated Receptor-α PPAR Research. 2006;1 In Press. [Google Scholar]
12. Sumanasekera WK, Tien ES, Turpey R, Vanden Heuvel JP, Perdew GHEvidence That Peroxisome Proliferator-activated Receptor alpha Is Complexed with the 90-kDa Heat Shock Protein and the Hepatitis Virus B X-associated Protein 2. J Biol Chem. 2003;278:4467–4473.[PubMed][Google Scholar]
13. Sumanasekera WK, Tien ES, Davis JW, 2nd, Turpey R, Perdew GH, Vanden Heuvel JPHeat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry. 2003;42:10726–10735.[PubMed][Google Scholar]
14. Patel H, Truant R, Rachubinski RA, Capone JPActivity and subcellular compartmentalization of peroxisome proliferator-activated receptor alpha are altered by the centrosome-associated protein CAP350. J Cell Sci. 2005;118:175–186.[PubMed][Google Scholar]
15. Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJSelective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol. 2002;16:707–721.[PubMed][Google Scholar]
16. El-Tanani MK, Green CDTwo separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol. 1997;11:928–937.[PubMed][Google Scholar]
17. Smith CLCross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod. 1998;58:627–632.[PubMed][Google Scholar]
18. Bunone G, Briand PA, Miksicek RJ, Picard DActivation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J. 1996;15:2174–2183.[Google Scholar]
19. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzer D, Chambon PActivation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. Science. 1995;270:1491–1494.[PubMed][Google Scholar]
20. Vanden Heuvel JPPeroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci. 1999;47:1–8.[PubMed][Google Scholar]
21. Rokos CL, Ledwith BJPeroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells. J Biol Chem. 1997;272:13452–13457.[PubMed][Google Scholar]
22. Ledwith BJ, Johnson TE, Wagner LK, Pauley CJ, Manam S, Galloway SM, Nichols WWGrowth regulation by peroxisome proliferators: opposing activities in early and late G1. Cancer Res. 1996;56:3257–3264.[PubMed][Google Scholar]
23. Lazennec G, Canaple L, Saugy D, Wahli WActivation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol. 2000;14:1962–1975.[Google Scholar]
24. Zhou YC, Waxman DJ. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b. J Biol Chem. 1999;274:2672–2681.[PubMed]
25. Vanden Heuvel JPPeroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J Nutr. 1999;129:575S–580S.[PubMed][Google Scholar]
26. Shalev A, Siegrist-Kaiser CA, Yen PM, Wahli W, Burger AG, Chin WW, Meier CAThe peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. Endocrinology. 1996;137:4499–4502.[PubMed][Google Scholar]
27. Passilly P, Schohn H, Jannin B, Malki MC, Boscoboinik D, Dauca M, Latruffe NPhosphorylation of peroxisome proliferator-activated receptor alpha in rat Fao cells and stimulation by ciprofibrate. Biochem Pharmacol. 1999;58:1001–1008.[PubMed][Google Scholar]
28. Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, Pernin A, Takeshita A, Chin WW, Burger AG, Meier CARegulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem. 1999;274:10505–10510.[PubMed][Google Scholar]
29. Vanden Heuvel JP, Kreder D, Belda B, Hannon DB, Nugent CA, Burns KA, Taylor MJComprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14,643. Toxicol Appl Pharmacol. 2003;188:185–198.[PubMed][Google Scholar]
30. Barger PM, Browning AC, Garner AN, Kelly DPp38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. J Biol Chem. 2001;276:44495–44501.[PubMed][Google Scholar]
31. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DPDeactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723–1730.[Google Scholar]
32. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels BStatin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423–1432.[Google Scholar]
33. Gray JP, Burns KA, Leas TL, Perdew GH, Vanden Heuvel JPRegulation of peroxisome proliferator-activated receptor alpha by protein kinase C. Biochemistry. 2005;44:10313–10321.[PubMed][Google Scholar]
34. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur CThe protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol. 2004;18:1906–1918.[PubMed][Google Scholar]
35. Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, Oh GT, Yoon M, Lee KU, Park JYAMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun. 2006;340:291–295.[PubMed][Google Scholar]
36. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JBAdiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006;55:2562–2570.[PubMed][Google Scholar]
37. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain JStructure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol. 2001;8:593–596.[PubMed][Google Scholar]
38. Frame S, Cohen PGSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359:1–16.[Google Scholar]
39. Grimes CA, Jope RSThe multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65:391–426.[PubMed][Google Scholar]
40. Lazennec G, Canaple L, Saugy D, Wahli WActivation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol. 2000;14:1962–1975.[Google Scholar]
41. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen KPeroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem. 2001;276:3175–3182.[PubMed][Google Scholar]
42. Krogsdam AM, Nielsen CA, Neve S, Holst D, Helledie T, Thomsen B, Bendixen C, Mandrup S, Kristiansen KNuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. Biochem J. 2002;363:157–165.[Google Scholar]
43. Han S, Ritzenthaler JD, Wingerd B, Roman J. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J Biol Chem. 2005;280:33240–33249.[PubMed]
44. Kramer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, Kannisto K, Wallberg-Henriksson H, Ehrenborg E, Zierath JR, Krook ADirect activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes. 2005;54:1157–1163.[PubMed][Google Scholar]
45. Hu E, Kim JB, Sarraf P, Spiegelman BMInhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science. 1996;274:2100–2103.[PubMed][Google Scholar]
46. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VKTranscriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site. J Biol Chem. 1997;272:5128–5132.[PubMed][Google Scholar]
47. Camp HS, Tafuri SRRegulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem. 1997;272:10811–10816.[PubMed][Google Scholar]
48. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Moller DEInsulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 1996;271:31771–31774.[PubMed][Google Scholar]
49. Camp HS, Tafuri SR, Leff Tc-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology. 1999;140:392–397.[PubMed][Google Scholar]
50. Shao DL, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MAInterdomain communication regulating ligand binding by PPAR-gamma. Nature. 1998;396:377–380.[PubMed][Google Scholar]
51. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM, Jr, Nicholson ACTransforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem. 2000;275:1241–1246.[PubMed][Google Scholar]
52. Rochette-Egly CNuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 2003;15:355–366.[PubMed][Google Scholar]
53. Floyd ZE, Stephens JMInterferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem. 2002;277:4062–4068.[PubMed][Google Scholar]
54. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CRObesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med. 1998;339:953–959.[PubMed][Google Scholar]
55. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MAGenetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell. 2003;5:657–663.[PubMed][Google Scholar]
56. Akahoshi T, Namai R, Murakami Y, Watanabe M, Matsui T, Nishimura A, Kitasato H, Kameya T, Kondo HRapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum. 2003;48:231–239.[PubMed][Google Scholar]
57. Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M, Takahashi J, Della Vecchia K, Kondo T, Aiello LP, King GLAdipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. Faseb J. 2006;20:1203–1205.[PubMed][Google Scholar]
58. Leff TAMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochem Soc Trans. 2003;31:224–227.[PubMed][Google Scholar]
59. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas EThiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291:E175–181.[PubMed][Google Scholar]
60. Gampe RTJ, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HEAsymetry in the PPARγ/RXRα cyrstal structure reveals the molecular basis of heterodimerization among nuclear receptors. Molecular Cell. 2000;5:545–555.[PubMed][Google Scholar]
61. Gorla-Bajszczak A, Juge-Aubry C, Pernin A, Burger AG, Meier CAConserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR. Mol Cell Endocrinol. 1999;147:37–47.[PubMed][Google Scholar]
62. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JDEvidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha) Carcinogenesis. 1998;19:43–48.[PubMed][Google Scholar]
63. Gervois P, Torra IP, Chinetti G, Grotzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, Staels BA truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol. 1999;13:1535–1549.[PubMed][Google Scholar]
64. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VKA dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma- mediated adipogenesis. J Biol Chem. 2000;275:5754–5759.[PubMed][Google Scholar]
65. Chen S, Johnson BA, Li Y, Aster S, McKeever B, Mosley R, Moller DE, Zhou GBoth coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPARgamma) function. J Biol Chem. 2000;275:3733–3736.[PubMed][Google Scholar]
66. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, Desvergne B. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. J Biol Chem. 1997;272:25252–25259.[PubMed]
67. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MAInterdomain communication regulating ligand binding by PPAR-gamma. Nature. 1998;396:377–380.[PubMed][Google Scholar]
68. Deeb SS, Fajas L, Nemoto M, Pihlajamaeki J, Mykkaenen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx JA Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet. 1998;20:284–287.[PubMed][Google Scholar]